Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Clinical Research
  • Published:

The association of cancer-specific anxiety with disease aggressiveness in men on active surveillance of prostate cancer

Prostate Cancer and Prostatic Diseases volume 24, pages 335–340 (2021)Cite this article

Subjects

Abstract

Background

Active surveillance (AS) provides appropriate prostate cancer (PCa)-specific survival while minimizing morbidity, but underlying worry of PCa can generate anxiety. The aim of the study is to evaluate anxiety levels in men on AS and how anxiety relates to disease characteristics and treatment decision-making.

Methods

A retrospective analysis was conducted using all 302 subjects from the Reduction by Dutasteride of clinical progression Events in Expectant Management (REDEEM) study. Prostate biopsies were obtained at 18 and 36 months. Anxiety was measured at baseline and 3, 6, 12, 18, and 36 months post-randomization using the MAX-PC (Memorial general anxiety scale for PCa) questionnaire. Univariable and multivariable analysis of the association of disease aggressiveness (PSA levels, percentage of positive cores, and maximum core involvement) and anxiety levels were performed. Cox regression was used to analyze time to progression to discontinuation of active surveillance as a function of baseline anxiety.

Results

Overall, MAX-PC scores decreased from moderate at baseline with slight increases after receiving PSA results at 18 months, followed by more decline. Percentage of positive cores was associated with baseline anxiety (P = 0.02). The association remained when controlling for age, race, number of cores sampled, body mass index, prostate volume, and maximum core length (P = 0.003). In univariable and multivariable analysis, baseline anxiety was not significantly associated with time to progression to discontinuation of active surveillance.

Conclusions

In evaluating the natural history of anxiety levels among patients with prostate cancer undergoing active surveillance, there was a decline of anxiety levels over time, with increases after receiving PSA results. Moreover, we found that disease aggressiveness measured by percentage of positive biopsy cores was associated with baseline levels of anxiety. However, anxiety had no impact on clinical or therapeutic progression.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Natural history of MAX-PC scores in men undergoing active surveillance for prostate cancer.
Fig. 2: Kaplan–Meier curve of progression of discontinuation of active surveillance by anxiety levels.

Similar content being viewed by others

Code availability

All computer code used to generate results is available upon request.

References

  1. Klotz L, Vesprini D, Sethukavalan P, Jethava V, Zhang L, Jain S, et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol. 2015;33:272–7.

    Article  Google Scholar 

  2. Dall’Era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR, et al. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer. 2008;112:2664–70.

    Article  Google Scholar 

  3. van den Berg RCN, Essink-Bot ML, Roobol MJ, Schröder FH, Bangma CH, Steyerberg EW. Do anxiety and distress increase during active surveillance for low risk prostate cancer? J Urol. 2010;183:1786–91.

    Article  Google Scholar 

  4. Marzouk K, Assel M, Ehdaie B, Vickers A. Long-term cancer specific anxiety in men undergoing active surveillance of prostate cancer: findings from a large prospective cohort. J Urol. 2018;200:1250–5.

    Article  Google Scholar 

  5. Vasarainen H, Lokman U, Ruutu M, Taari K, Rannikko A. Prostate cancer active surveillance and health-related quality of life: results of the Finnish arm of the prospective trial. BJU Int. 2012;109:1614–9.

    Article  Google Scholar 

  6. Chien CH, Chuang CK, Liu KL, Wu CTE, Pang ST, Chang YH. Positive and negative affect and prostate cancer-specific anxiety in Taiwanese patients and their partners. Eur J Oncol Nurs. 2018;37:1–11.

    Article  Google Scholar 

  7. Tavlarides AM, Ames SC, Diehl NN, Joseph RW, Castle EP, Thiel DD, et al. Evaluation of the association of prostate cancer-specific anxiety with sexual function, depression and cancer aggressiveness in men 1 year following surgical treatment for localized prostate cancer. Psychooncology. 2013;22:1328–35.

    Article  Google Scholar 

  8. Ruane-McAteer E, Porter S, O’Sullivan J, Dempster M, Prue G. Investigating the psychological impact of active surveillance or active treatment in newly diagnosed favorable-risk prostate cancer patients: a 9-month longitudinal study. Psychooncology. 2019;28:1743–52.

    Article  Google Scholar 

  9. Watts S, Leydon G, Birch B, Prescott P, Lai L, Eardley S, et al. Depression and anxiety in prostate cancer: a systematic review and meta-analysis of prevalence rates. BMJ Open. 2014;4:e003901.

    Article  Google Scholar 

  10. Tan HJ, Marks LS, Hoyt MA, Kwan L, Filson CP, Macairan M, et al. The relationship between intolerance of uncertainty and anxiety in men on active surveillance for prostate cancer. J Urol. 2016;195:1724–30.

    Article  Google Scholar 

  11. Dale W, Bilir P, Han M, Meltzer D. The role of anxiety in prostate carcinoma: a structured review of the literature. Cancer. 2005;104:467–78.

    Article  Google Scholar 

  12. Fleshner NE, Lucia MS, Egerdie B, Aaron L, Eure G, Nandy I, et al. Dutasteride in localised prostate cancer management: The REDEEM randomised, double-blind, placebo-controlled trial. Lancet. 2012;379:1103–11.

    Article  CAS  Google Scholar 

  13. Roth A, Nelson CJ, Rosenfeld B, Warshowski A, O’Shea N, Scher H, et al. Assessing anxiety in men with prostate cancer: further data on the reliability and validity of the Memorial Anxiety Scale for Prostate Cancer (MAX-PC). Psychosomatics. 2006;47:340–7.

    Article  Google Scholar 

  14. Ene KW, Nordberg G, Johansson FG, Sjöström B. Pain, psychological distress and health-related quality of life at baseline and 3 months after radical prostatectomy. BMC Nurs. 2006;5:8.

    Article  Google Scholar 

  15. Burnet KL, Parker C, Dearnaley D, Brewin CR, Watson M. Does active surveillance for men with localized prostate cancer carry psychological morbidity? BJU Int. 2007;100:540–3.

    Article  Google Scholar 

  16. Burgess C, Cornelius V, Love S, Graham J, Richards M, Ramirez A. Depression and anxiety in women with early breast cancer: five year observational cohort study. Br Med J. 2005;330:702–5.

    Article  Google Scholar 

  17. Edwards B, Clarke V. The psychological impact of a cancer diagnosis on families: the influence of family functioning and patients’ illness characteristics on depression and anxiety. Psychooncology. 2004;13:562–76.

    Article  Google Scholar 

  18. Thorsteinsdottir TK, Valdimarsdottir H, Stranne J, Wilderäng U, Haglind E, Steineck G. Thinking about one’s own death after prostate-cancer diagnosis. Support Care Cancer. 2018;26:1665–73.

    PubMed  Google Scholar 

  19. Bill-Axelson A, Garmo H, Nyberg U, Lambe M, Bratt O, Stattin P, et al. Psychiatric treatment in men with prostate cancer—results from a nation-wide, population-based cohort study from PCBaSe Sweden. Eur J Cancer. 2011;47:2195–201.

    Article  Google Scholar 

  20. Dillard AJ, Scherer LD, Ubel PA, Alexander S, Fagerlin A. Anxiety symptoms prior to a prostate cancer diagnosis: associations with knowledge and openness to treatment. Br J Health Psychol. 2017;22:151–68.

    Article  Google Scholar 

  21. Cameron LD, Reeve J. Risk perceptions, worry, and attitudes about genetic testing for breast cancer susceptibility. Psychol Heal. 2006;21:211–30.

    Article  Google Scholar 

  22. Lu D, Andrae B, Valdimarsdóttir U, Sundström K, Fall K, Sparen P, et al. Psychologic distress is associated with cancer-specific mortality among patients with cervical cancer. Cancer Res. 2019;79:3965–72.

    Article  CAS  Google Scholar 

  23. Chien CH, Chuang CK, Liu KL, Li CL, Liu HE. Changes in decisional conflict and decisional regret in patients with localised prostate cancer. J Clin Nurs. 2014;23:1959–69.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of Illinois College of Medicine, Chicago, IL, USA

    Ushasi Naha, Michael R. Abern & Daniel M. Moreira

  2. Division of Urology, Department of Surgery and the Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA

    Stephen J. Freedland

  3. Urology Section, Veterans Affairs Medical Center, Durham, NC, USA

    Stephen J. Freedland

Authors
  1. Ushasi Naha
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen J. Freedland
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael R. Abern
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daniel M. Moreira
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel M. Moreira.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Naha, U., Freedland, S.J., Abern, M.R. et al. The association of cancer-specific anxiety with disease aggressiveness in men on active surveillance of prostate cancer. Prostate Cancer Prostatic Dis 24, 335–340 (2021). https://doi.org/10.1038/s41391-020-00279-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41391-020-00279-z

This article is cited by

Search

Advanced search

Quick links